Migraine Patients May Be at Increased Risk of Developing Rheumatoid Arthritis
Headache is a common symptom of many autoimmune conditions, including rheumatoid arthritis (RA). Whether that’s from the disease activity itself, …
Migraine News
Bye Bye RELPAX
I never bought lunch in grade school. I don’t know what I was more scared of at that age, ordering …
FDA Approves Emgality for Episodic Cluster Headache
One June 4, 2019 the FDA approved Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults. Emgality is …
FDA Approves New Nasal Spray Medication for Migraine Treatment
On January 30th, 2019, the United States Food and Drug Administration (FDA) approved a nasal spray for the treatment of …
Emgality Users, We Want to Hear From You!
Have you been prescribed Emgality and/or taken your first dose? If so, we’d like to hear from you. Please enter …
Emgality Approved for Migraine Prevention—Lilly Says Free for Some Insured Patients
Eli Lilly and Company received approval from the U.S. Food and Drug Administration (FDA) to market Emgality™ (galcanezumab-gnlm) for migraine …
Ajovy Approved by FDA as Second CGRP Blocker for Migraine Prevention
Today, the U.S. Food and Drug Administration (FDA) approved Ajovy™ (fremanezumab-vfrm) for the prevention of migraine in adults. Ajovy is …
How’s Your Relationship with Your Doctor? Take our Survey!
Do you feel heard by your doctor? Do your questions get answered? We want to hear from you! We’re conducting …
Phase 3 Clinical Trials’ Data on Oral CGRP Presented at AHS
The American Headache Society (AHS) hosted its Annual Scientific Meeting this past week, which included several late-breaking presentations from Biohaven …
Oral CGRPs Phase 3 Clinical Trial Now Recruiting
Biohaven Pharmaceuticals announced on March 6, 2018 that patients may enroll in a Phase 3 clinical trial to evaluate the …
Aimovig Approved by FDA as First Calcitonin-Gene-Related Peptide (CGRP) Blocker for Migraine Prevention
The U.S. Food and Drug Administration (FDA) has approved Aimovig as the first calcitonin-gene-related peptide (CGRP) blocker for the preventive …
Take the Clinical Trial Patient Experience Survey!
Have you participated in a clinical trial? We want to hear more about your experience! We are conducting a short …
Out of My Head Documentary
At this year’s Headache on the Hill, migraine advocates had the opportunity to attend the premiere of the highly anticipated, …
New Look, Same Great Community!
You might notice a few changes in the way things look when you visit Migraine.com. Never fear! You still have …
Ajovy Users, We Want to Hear From You!
Have you been prescribed Ajovy and/or taken your first dose? If so, we’d like to hear from you. Please enter …
Patient Input on CGRP Needed by May 8th
It’s time to rally the troops! Those who live with migraine disease have a chance to make an impact on the …
The Migraine World Summit
2019 Update: The free virtual Migraine World Summit is taking place March 20-28, 2019. Registration is required. Book your spot …
Headache on the Hill 2018 – How You Can Get Involved Now
On February 12 and 13, 2018, the Alliance for Headache Disorders Advocacy (AHDA) held its annual Headache on the Hill …
FDA Announces OTC Migraine Medications Will Now Include New Warning Label
In February 2015, a group of physicians, led by Dr. Jonathan H. Smith of the Department of Neurology at the …
Non-invasive Vagus Nerve Stimulator Approved to Treat Migraine Pain
On January 29, 2018, the FDA approved gammaCORE, a hand-held, non-invasive, vagus nerve stimulator (nVNS) for the treatment of migraine …